2024-11-25 - Analysis Report
## Teladoc Health Inc (TDOC) Stock Analysis Report

**1. Performance Comparison & Divergence:**

Teladoc Health (TDOC) has significantly underperformed the S&P 500 (VOO) over the period analyzed.  The cumulative return for TDOC is -63.29%, while VOO shows a 126.15% return. This represents a total divergence of **-189.44%**. The relative divergence of -0.63 indicates that TDOC's performance is considerably below the S&P 500, falling in the lower 63rd percentile of its historical performance relative to the index.

**Company Overview:** Teladoc Health Inc. provides virtual care services, including telehealth consultations and related healthcare solutions.


**Alpha & Beta Analysis:** The provided data shows high beta values (generally above 1), indicating high volatility and sensitivity to market movements.  The fluctuating alpha values suggest periods of both outperformance and underperformance relative to the market. Notably, recent years (2020-2024) show negative CAGR and high maximum drawdowns (MDD), reflecting significant losses.

**2. Recent Price Movement:**

* **Closing Price:** $10.62 (Last market: $11.36)
* **5-Day Moving Average:** $9.60
* **20-Day Moving Average:** $9.33
* **60-Day Moving Average:** $8.83

The price is currently above all three moving averages, suggesting a potential short-term upward trend. The gap between the last market price and closing price ($11.36 vs $10.62) might indicate a minor pullback after a possible short-term surge or correction.

**3. Technical Indicators & Expected Return:**

* **RSI (69.15):**  Approaching overbought territory, suggesting potential for a near-term correction.
* **PPO (0.97):** Positive value indicates bullish momentum.
* **Delta_Previous_Relative_Divergence (0.52, +):** Shows a recent increase in relative strength.
* **Expected Return (0.0%):**  The expected return is currently zero, implying no significant expected outperformance against the S&P 500 over the long term (2+ years) based on the current data.

**4. Recent Financial Performance & Outlook:**

The company's recent financial results show consistently negative EPS and relatively stable revenue around $0.64-$0.66B.  The large negative EPS, especially in August 2024 (-$4.92), warrants further investigation.  The absence of an earnings forecast for the latest report prevents a complete analysis.  The significantly negative EPS raises serious concerns regarding profitability and future growth prospects.

**5. Revenue and Profitability:**

The revenue is relatively stable but profit margins have recently slightly decreased from around 71-72% to 70%.  The negative ROE figures demonstrate substantial losses in profitability and raise concerns about the financial health of the company.

**6. Capital and Profitability:**

The negative ROE across quarters indicates consistent losses. The significant fluctuation in equity (e.g., from $2.29B to $1.50B) points to potential financial challenges and warrants closer examination.

**7. News and Recent Issues:**

*(This section requires access to real-time news sources such as Shacknews and FINBOLD. Please provide specific news articles for a comprehensive analysis.  A general search for Teladoc Health's recent news will be necessary to fulfill this section.)*  I need current news to analyze recent market outlook, analyst opinions, and performance highlights.


**8. Summary:**

Teladoc Health (TDOC) is currently experiencing significant underperformance relative to the S&P 500, reflected in its negative cumulative return and substantially lower relative strength.  Technical indicators suggest potential short-term upward movement, but the negative EPS and ROE figures raise serious concerns about the company's long-term financial health and viability.  The recent price action may involve short-term volatility and is not necessarily reflective of long-term trend.  The lack of a positive long-term expected return and persistently negative earnings significantly affect the investment case. Before investing, a thorough understanding of the underlying reasons for the negative earnings and the company's restructuring plans (if any) is crucial.


**9. Disclaimer:** This report is based on the provided data and publicly available information. It is not financial advice.  Investing in the stock market involves risk, and past performance is not indicative of future results.  Always conduct thorough due diligence and consider consulting with a financial advisor before making any investment decisions.
